Going beyond the obvious conclusion with anti-LAG3 therapy
An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.
Winners, losers and risers... who goes where in the final analysis?
Rising stars become supernovas or disappear into a black hole of R&D - a look at what we can learn from one company's early stage compounds
Commentary on data presented at ESMO20 for PIONeeR Lung Cancer Immunotherapy Project
A look at one oncology biotech company's early pipeline and how it fits in with the emerging landscape
Surprising new developments in early stage breast and metastatic prostate cancers
Reflections on data in early breast cancer and NSCLC presented on Sunday at #ESMO20
Solid tumour highlights from ESMO not including breast cancer
Breast cancer highlights from Saturday at ESMO20
Commentary on Day 1 at ESMO20 and data presented in the mini oral sessions
What to watch out for this weekend in targeted therapies and early stage new product development
Five IO areas in early stage development to watch out for at ESMO20
Can we predict the future cancer drug combinations from emerging new targets?
A look at progress and new developments in cancer biomarker developments